Common Stock ($0.50 par value)
- Symbol
- MRK
- Exchange
- NYSE
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.02 · 8-K
Merck & Co., Inc.
MRKNYSEEQUITYCurrent
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) Incorporated by reference is a press release issued by Merck & Co., Inc. (the “Company”) on October 13, 2026, attached as Exhibit 99.1, announcing the election of Paul J. Diaz to the Company’s Board of Directors (the “Board”), effective November 1, 2026.…
Press release in this filing
Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors →Company context
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world - and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Current securities
Registered securities in this filing
Merck & Co., Inc. · 8-K · Filed 2026-10-13
3.250% Notes due 2032
- Symbol
- MRK/32
- Exchange
- NYSE
- Classification
- DEBT
2.500% Notes due 2034
- Symbol
- MRK/34
- Exchange
- NYSE
- Classification
- DEBT
1.375% Notes due 2036
- Symbol
- MRK 36A
- Exchange
- NYSE
- Classification
- DEBT
3.500% Notes due 2037
- Symbol
- MRK/37
- Exchange
- NYSE
- Classification
- DEBT
3.700% Notes due 2044
- Symbol
- MRK/44
- Exchange
- NYSE
- Classification
- DEBT
3.750% Notes due 2054
- Symbol
- MRK/54
- Exchange
- NYSE
- Classification
- DEBT
Disclosure sections
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d) Incorporated by reference is a press release issued by Merck & Co., Inc. (the “Company”) on October 13, 2026, attached as Exhibit 99.1, announcing the election of Paul J. Diaz to the Company’s Board of Directors (the “Board”), effective November 1, 2026. The Board appointed Mr. Diaz as a member of both the Audit Committee and the Research Committee of the Board.
For his service on the Board, Mr. Diaz will receive compensation as a non-employee director in accordance with the Company’s non-employee director compensation practices described under the “Director Compensation” section of the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 8, 2026.
Mr. Diaz has no arrangements or understandings with any other person pursuant to which he was elected to the Board, nor does he have a relationship or related transaction with the Company that would require disclosure pursuant to Item 404(a) of Regulation S-K of the Securities and Exchange Commission in connection with his appointment as a director of the Company.